- Establishes leadership position in B-cell cancer vaccines
- Includes FDA IND-ready PD-1 checkpoint inhibitor for Phase 1 trial
- National Cancer Institute funded, FDA appoved Phase II HER-2 trial
- Broad patent estate
- Expands B-cell peptide vaccine pipeline with 6 additional cancer targets
MELBOURNE Australia 7 June 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced it has signed an exclusive, world-wide licence to the entire body of cancer vaccine work and intellectual property developed by Professor Pravin T. P. Kaumaya of The Ohio State University Wexner Medical Center and The Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Mayo Clinic.
For further information please download PDF attached:
Download this document